Cardiomyopathy laboratory findings

Cardiomyopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiomyopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Guidelines
2023 ESC Guideline Recommendations
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Case Studies
Case #1
Cardiomyopathy laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiomyopathy laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiomyopathy laboratory findings
CDC on Cardiomyopathy laboratory findings
Cardiomyopathy laboratory findings in the news
Blogs on Cardiomyopathy laboratory findings
Directions to Hospitals Treating Cardiomyopathy
Risk calculators and risk factors for Cardiomyopathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub, MD; Edzel Lorraine Co, DMD, MD[2]

Overview

Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure. Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome. Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.

Cardiomyopathy Laboratory Findings

• Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure.
• Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome.
• Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.
• Elevated troponin levels indicate ischemic heart disease, and should be investigated as much, till coronary arterial disease is ruled out.
• Elevated iron saturation and ferritin are indicative of hemochromatosis as a cause of cardiomyopathy.